Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Prothena Corporation plc - Ordinary Shares (NQ:PRTA)

9.550 +0.240 (+2.58%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Prothena Corporation plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
  On Thursday, 369 companies hit new 52-week lows. 
Via Benzinga
News headline image
Expert Ratings for Prothena Corp ↗
 
Via Benzinga
News headline image
JMP Securities Maintains Outperform Rating for Prothena Corp: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Earnings Scheduled For August 3, 2023 ↗
Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million. 
Via Benzinga
News headline image
Prothena Corp's Earnings Outlook ↗
 
Via Benzinga
News headline image
Prothena to Participate in Upcoming Healthcare Conferences
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports Second Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Report Second Quarter 2023 Financial Results on August 3
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Presents New Research in the Treatment of Alzheimer’s Disease at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
News headline image
Expert Ratings for Prothena Corp ↗
 
Via Benzinga
News headline image
8 Analysts Have This to Say About Prothena Corp ↗
 
Via Benzinga
News headline image
Prothena to Present New Data from Alzheimer’s Disease Programs at Alzheimer’s Association International Conference® 2023 (AAIC®)
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab
From Prothena Corporation plc
Via Business Wire
News headline image
Looking Into Prothena Corp's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Recap: Prothena Corp Q1 Earnings ↗
 
Via Benzinga
News headline image
Prothena to Participate in Jefferies 2023 Healthcare Conference
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Reports First Quarter 2023 Financial Results and Business Highlights
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena Corp Earnings Preview ↗
 
Via Benzinga
News headline image
Where Prothena Corp Stands With Analysts ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Prothena Corp ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Another Sucess In Alzheimer’s Disease ↗
Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments? 
Via Talk Markets
News headline image
Prothena to Report First Quarter 2023 Financial Results on May 4
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in 2023 Bank of America Healthcare Conference
From Prothena Corporation plc
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 24, 2023 ↗
 
Via Benzinga
News headline image
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial
From Walgreens
Via Business Wire
News headline image
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023
From Prothena Corporation plc
Via Business Wire
News headline image
Prothena to Participate in Stifel 2023 Virtual CNS Days
From Prothena Corporation plc
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.